Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Xing-Wang Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8145-1476; OpenAlex author ID A5100945921. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
4
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

  1. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer. Last author DOI 10.1016/j.phymed.2024.155377↗
  2. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model. Last author DOI 10.1007/s00432-022-04036-8↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Su‐Li Zhu · 1 shared paper, 2024 · strength 0.24
  2. Lijuan Deng · 1 shared paper, 2024 · strength 0.24
  3. Said Ahmed Bahwal · 1 shared paper, 2022 · strength 0.16
  4. Taofang Hao · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.